Artificial Intelligence

Science and research of the universe; quantum science
#Collaboration #Deep learning #Deep tech #Life sciences #Quantum computing #Research

Start-up accelerator to unlock potential in quantum science 

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating life science research, has launched a new deep tech accelerator start-up programme, the Deep Tech Lab – Quantum, to propel emergent and disruptive quantum science and biotechnology solutions toward the marketplace.   Deep tech and quantum science have… Read More

#News

Artificial intelligence
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Drug targets #Machine learning

Can artificial intelligence help craft new medicines?

Listen to this article on the DDW Podcast: Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before. A bullet for cure The year was 1907, and Paul Ehrlich, the German Nobel laureate had proposed the idea of a magic bullet to cure diseases. The magic… Read More

#Exclusive Content

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Interview

How generative AI could improve drug discovery

Listen to this article on the DDW Podcast: Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within… Read More

#Exclusive Content

Histology slides
#AACR 2023 #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Machine learning #Oncology

AI can predict the risk of distant recurrence in endometrial cancer

An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine… Read More

#Cancer Research #News #Trending News

Ophthalmologist looks at retinal scan
#Artificial intelligence (AI) #Endogena Therapeutics #Ophthalmology #Phase I trial #Phase II trial #Retinitis pigmentosa

Retinitis pigmentosa drug proved safe in Phase I/IIa study

Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. Given the positive safety and tolerability profile, the study will now enrol patients into the expansion cohort, using the highest… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Atomic AI #Machine learning #Molecular Biology #RNA

Using AI to design RNA-based medicines

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Diana Spencer spoke to Raphael Townshend, PhD, Founder and CEO of Atomic AI, about the advantages of combining two such exciting technologies. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery… Read More

#Exclusive Content

Scientist looking through microscope
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Automation / robotics #Financing #Fundraising #Iktos #Investment

AI and robotics drug discovery company raises €15.5M

Iktos has raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company to launch Iktos Robotics; a drug… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Contract Research Organisations (CROs) #Machine learning #Rare disease #Rare Disease Day

How AI can be utilised to improve rare disease drug development

By Lucy Radley, Head of EU Regulatory Development, ProPharma. A rare disease is defined as a condition which affects less than one in 2000 people. Although individually they are very rare, collectively they are common with one in 17 people (around 3.5 million) in the UK being affected by a… Read More

#Exclusive Content #Opinion

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #Drug discovery #Machine learning #Medicinal chemistry #Webinar

Connected chemistry: Choose the most promising drug candidates

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More

Webinar date:
#News

Neuron and antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antiverse #Drug discovery #Funding #Investment #Machine learning

AI company raises $3m to develop antibodies targeting GPCRs

Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.  The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Atomic AI #Molecular Biology #RNA #Turning Science into Business

Turning science into business: Merging AI and RNA

New kids on the block, Atomic AI, recently closed a $35 million series A financing. DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. … Read More

#Exclusive Content #Start-up Zone

#AI / data analytics / healthtech / informatics #Data science #Lab automation #Life science #Machine learning #Proteins #Proteomics #SLAS2023 #Therapeutics

Don’t miss the DDW Events podcast series for SLAS2023

Today marks the start of SLAS2023 in San Diego. Over the last week, DDW’s Megan Thomas has narrated five articles from the SLAS2023 supplement as part of the DDW Events podcast series. Episodes include: A Welcome to SLAS 2023 Acquiring deeper insights and acceleration with AI Connecting… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Data management #Data science #SLAS2023

Harnessing the power of data science and AI in life sciences

Abbey Vangeloff is the Director of Business Development, Life Sciences, at Yahara Software. She will be chairing a session at SLAS2023. DDW’s Megan Thomas catches up with Vangeloff to learn why AI and data science are so important for the future of the sector. On SLAS2023  Abbey Vangeloff says that… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Cloud computing #High throughput screening #Lab automation #Machine learning #SLAS2023

How ML and automation are changing the future of protein therapeutics

Kristen Hopson, Vice President of Preclinical Discovery and Development at Generate Biomedicines, and Yue Liu, Associate Director, HTS at Generate Biomedicines, reflect on the impact of artificial intelligence (AI), machine learning (ML), cloud computing, and advances in laboratory automation and high-throughput screening (HTS) on life science research. Proteins are the basic… Read More

#Exclusive Content

#Biomedicine #Cloud computing #High throughput screening #Lab automation #Life sciences #Machine learning #Proteins #Proteomics #SLAS2023 #Therapeutics

Podcast: ML and lab automation are changing protein therapeutics

Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March) DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode four, How machine learning and lab automation are changing the… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #Drug discovery #Machine learning #Medicinal chemistry #Webinar

Webinar: Choose the right drug candidates from your hit list

DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More

Webinar date:
#News